BearingPoint Posts Strong Full-year Results Amid Record Growth
7.3.2023 10:45:00 EET | Business Wire | Press release
Management and technology consultancy BearingPoint closed the year 2022 with record high growth: full-year 2022 adjusted revenues grew 24 percent to €862 million compared to the previous year, mainly driven by new revenue streams and innovative business services. BearingPoint delivered over 1,400 projects for clients in more than 40 countries around the globe. To support its strong development, BearingPoint increased the number of its people by 23 percent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005707/en/
Kiumars Hamidian, Managing Partner of BearingPoint. (Photo: Business Wire)
“2022 was an outstanding year for BearingPoint,” said Kiumars Hamidian, Managing Partner of BearingPoint. “Throughout the year, we observed increasing demand for our business services, particularly digital transformation programs. We won significant projects across all market segments, further strengthening our trustful collaboration with clients. In 2023 we want to build on the achievements of 2022, continue to accelerate our strategic ambitions, and target €1 billion in revenue.”
Strategic acquisitions and one joint venture strengthen the BearingPoint portfolio
In 2022 BearingPoint completed four strategic acquisitions that enhanced and strengthened the BearingPoint portfolio, particularly in the areas of sustainability (I Care), financial services (Levo Consultants), digital business transformation (Fekra), as well as the products portfolio (disphere tech). “Our acquisitions are an important component of our strategy execution. Besides organic growth, our strategic M&A activities support our ambitions for the coming years,” said Kiumars Hamidian.
Furthermore, BearingPoint established its first joint venture, Arcwide. The joint venture with IFS brings together professional business services, IFS cloud technology and innovation into a unique business transformation proposition to help companies significantly increase value creation.
With more than 300 people, the Products business unit was another highlight for BearingPoint, recording strong revenue growth of 25 percent. The BearingPoint Store expanded its portfolio of services and solutions to over 20 products. BearingPoint’s products have received both national and international recognition. One of its many awards was the 2022 SAP® Pinnacle Award in the Sustainability category.
A purpose-driven firm
BearingPoint heads into the future as a strong purpose-driven firm, focusing on people, innovation, and sustainability. “In 2022, we jointly refined and clarified our purpose as a team. ‘Together, we are more than business’ is the ideal we put into practice. Personally, I am very proud to see how our people live our purpose. As our people are at the core of our success, we continue to invest in talent development. With more than 2,000 participants in programs like Be.School, Yale, and the Oxford Said Business School, we have created a high-quality training curriculum for our people,” stated Kiumars Hamidian.
2023 – Strategy acceleration
In 2023 BearingPoint will focus on the acceleration of its strategy. The consultancy plans to invest approximately €300 million by 2026, primarily on strategic M&A activities and investments in developing its consulting and products portfolio.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 13,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005707/en/
Contact information
Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 14:00:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orc
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 14:00:00 EEST | Press release
Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring.” — Rasmus Madsen, CEO, Cebreo Medical Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit complianc
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release
QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom